Recurrent Cancer Clinical Trial
Official title:
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for "ultral-central" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Recruiting |
NCT05415475 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT04596865 -
Recurrence After Whipple's (RAW) Study
|
||
| Recruiting |
NCT06103617 -
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT05364905 -
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
|
||
| Recruiting |
NCT05396300 -
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT03441100 -
TCR-engineered T Cells in Solid Tumors: IMA202-101
|
Phase 1 | |
| Recruiting |
NCT05359445 -
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03686124 -
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04889742 -
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
|
Phase 2 | |
| Completed |
NCT03132038 -
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
|
Phase 2 | |
| Not yet recruiting |
NCT06208657 -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02410187 -
SBRT for Extra-cranial Oligorecurrent Tumor
|
Phase 2 | |
| Not yet recruiting |
NCT04784221 -
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse
|
Phase 2 | |
| Recruiting |
NCT05855811 -
PREventing Second Cancers With DOSTARlimab
|
Phase 2 | |
| Recruiting |
NCT05626829 -
Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT03941262 -
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06372574 -
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
|
Phase 1 | |
| Completed |
NCT05200195 -
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
|
||
| Completed |
NCT03760952 -
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
|